tzp-102
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2009 (NCT00889486)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Ghrelin receptorAGONIST
GHSR agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@H]1NC(=O)[C@@H](C)N(C)C(=O)[C@H](C2CC2)NC[C@@H](C)Oc2ccccc2CC[C@H](C)NC1=O- Mol. weight
- 500.68 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594424 ↗
Also known as
- tzp-102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01664637 | Phase 2 | Aug 1, 2012 | Tranzyme, Inc. |
| NCT01452815 | Phase 2 | Sep 1, 2011 | Tranzyme, Inc. |
| NCT00889486 | Phase 2 | Apr 1, 2009 | Tranzyme, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tranzyme, Inc. | For profit | 3 | 3 | 1 | 2009 |
1 organizations
Page 1 / 1